Market research
PTCT PTC Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 99.2857
- Dividend yield
- Not available
- Beta
- 0.55
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US69366J2006
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 99.2857
- Dividend yield
- Not available
- Beta
- 0.55
About
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PTCT discussion.
5 years, 4 months ago
PTC Therapeutics, Inc is currently in a long term downtrend where the price is trading 19.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.5.
PTC Therapeutics, Inc's total revenue rose by 23.2% to $119M since the same quarter in the previous year.
Its net income has increased by 4.3% to $-74M since the same quarter in the previous year.
Finally, its free cash flow fell by 216.6% to $-83M since the same quarter in the previous year.
Based on the above factors, PTC Therapeutics, Inc gets an overall score of 3/5.